WO2023033681A4 - 2-(5-aryl-4 h-1,2,4-triazol-3-yl)éthanamines substituées utilisées comme modulateurs du récepteur 1 associé aux amines à l'état de traces (taar1) - Google Patents
2-(5-aryl-4 h-1,2,4-triazol-3-yl)éthanamines substituées utilisées comme modulateurs du récepteur 1 associé aux amines à l'état de traces (taar1) Download PDFInfo
- Publication number
- WO2023033681A4 WO2023033681A4 PCT/RU2022/050272 RU2022050272W WO2023033681A4 WO 2023033681 A4 WO2023033681 A4 WO 2023033681A4 RU 2022050272 W RU2022050272 W RU 2022050272W WO 2023033681 A4 WO2023033681 A4 WO 2023033681A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- disease
- pharmaceutical composition
- group
- condition
- Prior art date
Links
- 102000004406 Trace amine-associated receptor 1 Human genes 0.000 title abstract 4
- 108090000946 Trace amine-associated receptor 1 Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 20
- 208000035475 disorder Diseases 0.000 claims abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 3
- 208000010877 cognitive disease Diseases 0.000 claims abstract 3
- 208000030159 metabolic disease Diseases 0.000 claims abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 3
- 208000020016 psychiatric disease Diseases 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 208000025966 Neurological disease Diseases 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 101000890887 Homo sapiens Trace amine-associated receptor 1 Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000036760 body temperature Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 238000005265 energy consumption Methods 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000007958 sleep Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des 2-(5-aryl-4H-1,2,4-triazol-3-yl)éthanamines substituées de formule générale 1 et leurs sels pharmaceutiquement acceptables qui sont des modulateurs du récepteur 1 associé aux amines à l'état de traces (TAAR1). L'invention concerne également le procédé de production des composés de formule 1, une composition pharmaceutique à base desdits composés et l'utilisation desdits composés et de la composition pharmaceutique pour le traitement d'une maladie, d'un trouble ou d'un état médié(e) par des récepteurs TAAR1, tel(le) que les troubles mentaux, les troubles cognitifs, les troubles métaboliques, les maladies neurologiques et neurodégénératives.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA202192214 | 2021-09-01 | ||
| EA202192214 EA043874B1 (ru) | 2021-09-01 | Замещенные 2-(5-арил-4н-1,2,4-триазол-3-ил)этанамины в качестве модуляторов ассоциированного со следовыми аминами рецептора 1 (taar1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023033681A1 WO2023033681A1 (fr) | 2023-03-09 |
| WO2023033681A4 true WO2023033681A4 (fr) | 2023-05-19 |
Family
ID=83690035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2022/050272 WO2023033681A1 (fr) | 2021-09-01 | 2022-09-01 | 2-(5-aryl-4 h-1,2,4-triazol-3-yl)éthanamines substituées utilisées comme modulateurs du récepteur 1 associé aux amines à l'état de traces (taar1) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023033681A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101176699B1 (ko) | 2006-10-19 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 아미노메틸-4-이미다졸 |
| ATE533755T1 (de) | 2006-11-02 | 2011-12-15 | Hoffmann La Roche | Substituierte 2-imidazole als modulatoren der mit spurenaminen assoziierten rezeptoren |
| ES2554843T3 (es) | 2012-01-12 | 2015-12-23 | F. Hoffmann-La Roche Ag | Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs) |
| WO2013131018A1 (fr) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
| WO2016015333A1 (fr) | 2014-08-01 | 2016-02-04 | F.Hoffmann-La Roche Ag | Dérivés de 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl |
-
2022
- 2022-09-01 WO PCT/RU2022/050272 patent/WO2023033681A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023033681A1 (fr) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101084193B (zh) | (r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓盐酸盐的晶型 | |
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| CN108473489A (zh) | Valbenazine盐及其多晶形物 | |
| JP2019512469A5 (fr) | ||
| JP7074750B2 (ja) | カルバモイルフェニルアラニノール化合物およびその使用 | |
| TWI320785B (en) | Dihydrospiro-[cycloalkyl]-pyrimidone derivatives and the use thereof | |
| US9763938B2 (en) | Substituted quinoxalines as positive allosteric modulators of mGluR4 | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| JP2014129386A (ja) | カルバモイル−シクロヘキサン誘導体の溶媒和物および結晶形態 | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| JP2021073300A5 (fr) | ||
| JP2023083528A5 (fr) | ||
| JP2015521642A5 (fr) | ||
| AU2017201916B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| JP2008519056A5 (fr) | ||
| CZ2003140A3 (cs) | Nová forma (R)-N-[5-methyl-8-(4-methylpiperazin-l-yl)-1,2,3,4-tetrahydro-2-naftyl]-4-morfolinobenzamidu | |
| WO2023033681A4 (fr) | 2-(5-aryl-4 h-1,2,4-triazol-3-yl)éthanamines substituées utilisées comme modulateurs du récepteur 1 associé aux amines à l'état de traces (taar1) | |
| JP5571072B2 (ja) | アルファアドレナリン介在症状の治療方法 | |
| JP2015521643A5 (fr) | ||
| WO2023033679A4 (fr) | Benzamides à substitution méthoxy(azacycloalkyl) utilisés en tant que modulateurs du récepteur 1 associé à une amine trace (taar1) | |
| WO2023033680A4 (fr) | 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazépines substituées utilisées comme modulateurs du récepteur 1 associé aux amines à l'état de traces (taar1) | |
| TWI251594B (en) | Preparation of substituted quinoxalines | |
| RU2012101227A (ru) | 1-(2-алкил-2,3-дигидро-бензофуран-4-ил)-пирролидин-3-иламинацильные соединения, фармацевтическая композиция и лекарственное средство на их основе и способ лечения или предупреждения мелатонергетических нарушений с их помощью | |
| CN104151242A (zh) | 二氢异喹啉类化合物及其在制备神经保护或抗抑郁药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22789351 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |